Secondary investments among biopharma companies 2018

This statistic depicts the percentage of biopharma companies that said they had select secondary financial priorities, according to a survey conducted during summer 2018. According to the survey, 67 percent of respondents indicated that research and development is a secondary priority for their company.

Percentage of biopharma companies that have select secondary financial priorities as of 2018

Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

October 2018

Region

Worldwide, United States

Survey time period

summer 2018

Number of respondents

60 executives

Special properties

30 from biopharma, 30 from medtech companies

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Coronavirus: the pharma and medtech response"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.